Associations between genetic polymorphisms in interleukin-10 and hematological oncology: evidence from a meta-analysis

Figures & data

Table 1. The characteristics of included studies.

First author, year	Country	Ethnicity	Type of disease	Sample size Case/Control	Genotypes (wtwt/wtmt/mtmt)		P-value for HWE	NOS score
					Cases	Controls
rs1800871 − 819 C/T
Amirzargar 2005	Iran	Mixed	CML	30/40	11/14/5	21/19/0	0.049	7
Cheng 2015	China	Asian	NHL	125/300	57/59/9	136/125/39	0.230	8
Fei 2015	China	Asian	AML	167/328	57/72/38	137/137/54	0.052	8
Haydaroglu 2017	Turkey	Caucasian	MM	113/113	60/46/7	56/47/10	0.975	7
Hellmig 2008	Germany	Caucasian	Lymphoma	84/351	45/32/7	210/124/17	0.811	7
kube 2007	Germany	Caucasian	NHL	409/193	225/164/20	106/77/10	0.403	8
Lech-Maranda 2004	France	Caucasian	NHL	199/112	107/81/11	53/46/13	0.536	8
Lech-Maranda 2007	Poland	Caucasian	NHL	175/112	92/68/15	53/46/13	0.536	8
Lim 2015	Malaysia	Mixed	NHL	317/330	NA	NA	NA	7
Lo 2016	Taiwan	Asian	ALL	266/266	170/85/11	142/96/28	0.059	7
Mazur 2005	Poland	Caucasian	MM	54/50	35/16/3	27/17/6	0.218	7
Minnicelli 2012	Brazil	Mixed	NHL	61/205	33/24/4	90/92/23	0.944	7
Nielsen 2015	Denmark	Caucasian	NHL	172/304	NA	NA	NA	7
Nursal 2016	Turkey	Caucasian	AML	42/85	15/21/6	49/32/4	0.670	8
Oduor 2014	USA	Mixed	NHL	117/88	32/61/24	28/39/21	0.311	7
Pehlivan 2014	Turkey	Caucasian	CML	60/74	25/32/3	37/33/4	0.330	8
Persico 2006	Italy	Caucasian	NHL	108/110	60/44/4	53/51/6	0.159	8
Rashed 2018	Turkey	Caucasian	AML	80/85	26/23/31	40/36/9	0.832	7
Yao 2013	China	Asian	AML	115/137	68/38/9	56/63/18	0.966	9
rs1800872 − 592 C/A
Amirzargar 2005	Iran	Mixed	CML	30/40	11/14/5	21/19/0	0.049	7
Bănescu 2019	Romania	Mixed	AML	226/406	117/99/10	222/158/26	0.765	8
Banu 2011	Romania	Caucasian	MM	80/100	NA	NA	NA	7
Breen 2003	USA	Mixed	NHL	138/1019	91/44/3	550/398/71	0.931	7
Cheng 2015	China	Asian	NHL	125/300	57/59/9	138/124/38	0.225	8
Fei 2015	China	Asian	AML	167/327	54/74/39	126/142/59	0.091	8
Haydaroglu 2017	Turkey	Caucasian	MM	113/113	60/46/7	56/47/10	0.975	7
Kasamatsu 2017	Japan	Asian	MM	128/202	11/66/51	16/95/91	0.196	8
kube 2007	Germany	Caucasian	NHL	409/193	225/164/20	106/77/10	0.403	8
Lech-Maranda 2004	France	Caucasian	NHL	199/112	107/81/11	53/46/13	0.536	8
Lech-Maranda 2007	Poland	Caucasian	NHL	175/112	92/68/15	53/46/13	0.536	8
Lo 2016	Taiwan	Asian	ALL	266/266	117/101/48	170/85/11	0.927	7
Mazur 2005	Poland	Caucasian	MM	54/50	35/16/3	27/17/6	0.218	7
Minnicelli 2012	Brazil	Mixed	NHL	61/205	33/24/4	90/92/23	0.944	7
Munro 2003	UK	Caucasian	HL	147/110	88/55/4	66/42/2	0.105	7
Nielsen 2015	Denmark	Caucasian	NHL	208/304	NA	NA	NA	7
Nursal 2016	Turkey	Caucasian	AML	42/85	15/21/6	49/32/4	0.670	8
Oduor 2014	USA	Mixed	NHL	117/88	32/61/24	28/39/21	0.311	7
Pehlivan 2014	Turkey	Caucasian	CML	60/74	25/32/3	37/33/4	0.330	8
Persico 2006	Italy	Caucasian	NHL	108/110	60/44/4	53/51/6	0.159	8
Yao 2013	China	Asian	AML	115/137	9/38/68	18/63/56	0.966	9
Zhang 2012	China	Asian	NHL	514/557	226/228/60	269/235/53	0.872	7
rs1800890 − 3575 T/A
Cheng 2015	China	Asian	NHL	125/300	117/8/0	278/22/0	0.510	8
Deng 2013	China	Asian	NHL	510/597	NA	NA	NA	7
Fernberg 2010	Sweden	Caucasian	NHL	2312/1838	847/1092/373	695/865/278	0.742	8
kube 2007	Germany	Caucasian	NHL	409/193	184/180/45	66/100/27	0.264	8
Lech-Maranda 2013	Poland	Caucasian	CLL	290/192	112/132/46	69/85/38	0.208	8
Liang 2009	USA	Mixed	CLL	39/102	19/16/4	33/48/21	0.645	7
Nieters 2006	Germany	Caucasian	Lymphoma	670/661	268/302/100	262/306/93	0.810	8
Rothman 2006	USA	Mixed	NHL	2049/3921	745/982/322	1593/1816/512	0.876	8
Yri 2012	Norway	Caucasian	HL	223/1048	81/104/38	390/528/130	0.017	8
rs1800896 − 1082 G/A
Abdel Rahman 2018	Turkey	Caucasian	NHL	100/100	26/51/23	28/59/13	0.038	7
Amirzargar 2005	Iran	Mixed	CML	30/40	17/13/0	34/6/0	0.609	7
Bănescu 2019	Romania	Mixed	AML	226/406	74/109/43	144/188/74	0.359	8
Banu 2011	Romania	Caucasian	MM	80/100	NA	NA	NA	7
Berglund 2005	Sweden	Caucasian	NHL	244/195	70/136/38	60/89/46	0.250	7
Cheng 2015	China	Asian	NHL	125/300	101/24/0	237/60/3	0.710	8
Cunningham 2003	Australia	Caucasian	NHL	63/164	26/25/12	41/82/41	1.000	7
Deng 2013	China	Asian	NHL	510/587	NA	NA	NA	7
Fei 2015	China	Asian	AML	167/328	75/70/22	159/134/35	0.398	8
Haydaroglu 2017	Turkey	Caucasian	MM	113/113	34/66/13	43/52/18	0.731	7
Hiroki 2015	Brazil	Mixed	ALL	67/75	23/31/13	33/32/10	0.615	7
Hosgood 2013	USA	Mixed	NHL	2459/4079	2107/312/40	3598/452/29	<0.001	7
kube 2007	Germany	Caucasian	NHL	409/193	111/210/88	55/90/48	0.358	8
Lech-Maranda 2013	Poland	Caucasian	CLL	292/192	82/152/58	48/94/50	0.774	8
Lech-Maranda 2004	France	Caucasian	NHL	199/112	55/100/44	45/47/20	0.217	8
Lech-Maranda 2007	Poland	Caucasian	NHL	175/112	56/87/32	45/47/20	0.217	8
Lim 2015	Malaysia	Mixed	NHL	317/330	NA	NA	NA	7
Lo 2016	Taiwan	Asian	ALL	266/266	205/50/11	202/52/12	0.001	7
Mazur 2005	Poland	Caucasian	MM	54/50	20/23/11	16/23/11	0.617	7
Minnicelli 2012	Brazil	Mixed	NHL	61/216	21/26/14	102/92/22	0.852	7
Munro 2003	UK	Caucasian	HL	147/111	30/69/48	24/55/32	0.968	7
Nedoszytko 2016	Poland	Caucasian	NHL	43/173	8/30/5	36/90/47	0.557	8
Nielsen 2015	Denmark	Caucasian	NHL	206/301	NA	NA	NA	7
Nieters 2006	Germany	Caucasian	Lymphoma	664/660	211/298/155	208/302/150	0.046	8
Nursal 2016	Turkey	Caucasian	AML	42/85	22/17/3	32/36/17	0.246	8
Oduor 2014	USA	Mixed	NHL	117/88	53/53/11	39/39/10	0.958	7
Ovsepyan 2015	Russia	Caucasian	CLL	231/314	85/106/40	91/142/81	0.094	7
Pehlivan 2014	Turkey	Caucasian	CML	60/74	31/22/7	28/36/10	0.769	8
Persico 2006	Italy	Caucasian	NHL	108/110	22/38/48	36/56/18	0.628	8
Rothman 2006	USA	Mixed	NHL	1893/3565	521/925/447	1089/1734/742	0.285	7
Sharif 2019	Sudan	Mixed	AML	30/30	11/13/6	11/16/3	0.417	7
Zheng 2001	Sweden	Caucasian	MM	72/107	15/36/21	23/56/28	0.612	7

Abbreviations: AML, acute myeloid leukemia; CML, chronic myelogenous leukemia; NHL, non-Hodgkin’s lymphoma; HL, Hodgkin’s lymphoma; MM, multiple myeloma; ALL, acute lymphoblastic leukemia; CLL, chronic lymphoblastic leukemia; wt, wild type; mt, mutant type; HWE, Hardy–Weinberg equilibrium; NOS, Newcastle–Ottawa scale; NA, not available.

Figure 1. Flowchart of study selection for the present study.

Systematic literature search of the present meta-analysis.

Table 2. Meta-analyses results of IL-10 polymorphisms and hematological oncology.

		Dominant comparison			Recessive comparison			Over-dominant comparison			Allele comparison
Variables	Sample size	p value	OR (95%CI)	I^2 statistic	p value	(95%CI)	I^2 statistic	p value	OR (95%CI)	I^2 statistic	p value	OR (95%CI)	I^2 statistic
rs1800871 − 819 C/T
Overall	2694/3283	0.81	1.02 (0.84–1.26)	68%	1.00	1.00 (0.68–1.47)	73%	0.56	0.96 (0.85–1.09)	0%	0.67	1.04 (0.88–1.22)	77%
Asian	673/1031	0.83	0.95 (0.62–1.46)	71%	0.83	0.92 (0.42–2.00)	85%	0.46	0.93 (0.76–1.13)	50%	0.81	0.95 (0.61–1.46)	87%
Caucasian	1496/1589	0.40	1.14 (0.84–1.53)	66%	0.07	0.76 (0.57–1.03)	25%	0.76	0.97 (0.83–1.15)	0%	0.35	1.11 (0.90–1.37)	66%
AL	670/901	0.87	1.06 (0.53–2.14)	87%	0.80	1.10 (0.54–2.24)	84%	0.30	0.84 (0.61–1.16)	51%	0.89	0.96 (0.56–1.66)	91%
CL	90/144	0.12	0.64 (0.37–1.13)	0%	0.45	3.11 (0.16–60.15)	70%	0.44	1.24 (0.72–2.17)	0%	0.08	0.68 (0.44–1.04)	35%
NHL	1683/1754	0.18	1.13 (0.95–1.34)	0%	0.009	0.66 (0.49–0.90)	0%	0.85	1.02 (0.85–1.22)	0%	0.50	1.06 (0.89–1.28)	62%
rs1800872 − 592 C/A
Overall	3256/4504	0.93	0.99 (0.81–1.21)	68%	0.94	1.01 (0.73–1.40)	67%	0.69	1.02 (0.92–1.13)	0%	0.63	0.96 (0.82–1.13)	76%
Asian	1315/1789	0.31	0.83 (0.57–1.20)	76%	0.35	1.42 (0.68–2.97)	88%	0.25	1.09 (0.94–1.26)	33%	0.87	0.97 (0.68–1.40)	90%
Caucasian	1595/1363	0.29	1.15 (0.89–1.48)	54%	0.17	0.78 (0.55–1.11)	1%	0.98	1.00 (0.84–1.19)	0%	0.23	1.08 (0.95–1.22)	34%
AL	590/815	<0.0001	0.57 (0.45–0.71)	44%	0.0005	3.23 (1.44–7.25)	79%	0.83	1.04 (0.71–1.53)	62%	0.31	0.73 (0.40–1.34)	92%
CL	90/114	0.12	0.64 (0.37–1.13)	0%	0.45	3.11 (0.16–60.15)	70%	0.44	1.24 (0.72–2.17)	0%	0.08	0.68 (0.44–1.04)	35%
NHL	2054/3000	0.005	1.23 (1.06–1.42)	0%	0.0004	0.60 (0.46–0.80)	0%	0.95	1.00 (0.87–1.14)	0%	0.0004	1.19 (1.08–1.31)	0%
MM	321/415	0.17	1.55 (0.83–2.92)	66%	0.25	0.78 (0.52–1.18)	0%	0.60	1.10 (0.78–1.54)	0%	0.28	1.15 (0.89–1.49)	0%
rs1800890 − 3575 T/A
Overall	6627/8852	0.87	0.99 (0.86–1.13)	62%	0.02	1.12 (1.02–1.24)	45%	0.97	1.00 (0.93–1.07)	0%	0.86	1.01 (0.90–1.13)	66%
Asian	635/897	0.03	0.78 (0.62–0.98)	0%	NA	NA 0%	NA NA	0%	NA	NA 0%
Caucasian	3904/3932	0.82	1.01 (0.92–1.11)	45%	0.38	1.06 (0.93–1.20)	33%	0.39	0.96 (0.88–1.05)	0%	0.71	1.02 (0.91–1.15)	54%
CL	329/294	0.19	1.26 (0.90–1.76)	43%	0.10	0.70 (0.45–1.07)	0%	0.96	0.99 (0.71–1.38)	0%	0.07	1.25 (0.98–1.58)	49%
NHL	5405/6849	0.54	0.94 (0.79–1.13)	72%	0.25	1.11 (0.93–1.33)	50%	0.62	1.02 (0.94–1.10)	33%	0.91	0.99 (0.85–1.16)	76%
rs1800896 − 1082 G/A
Overall	9314/13140	0.0005	0.89 (0.83–0.95)	43%	0.48	1.07 (0.89–1.29)	65%	0.09	1.06 (0.99–1.13)	31%	0.25	0.95 (0.86–1.04)	64%
Asian	1068/1481	0.24	0.90 (0.75–1.07)	0%	0.71	1.09 (0.69–1.74)	0%	0.93	1.01 (0.80–1.28)	0%	0.82	0.98 (0.80–1.19)	0%
Caucasian	3302/3266	0.98	1.00 (0.89–1.12)	44%	0.72	0.96 (0.75–1.21)	65%	0.34	1.05 (0.95–1.17)	42%	0.82	1.02 (0.89–1.15)	64%
AL	542/754	0.83	0.97 (0.77–1.24)	33%	0.97	1.01 (0.59–1.72)	38%	0.91	1.01 (0.79–1.30)	0%	0.94	1.01 (0.74–1.39)	59%
CL	613/620	0.72	1.10 (0.66–1.84)	70%	0.005	0.66 (0.50–0.89)	0%	0.61	1.12 (0.72–1.75)	65%	0.36	1.17 (0.84–1.63)	65%
NHL	7029/10625	<0.0001	0.84 (0.78–0.91)	28%	0.24 1	20 (0.89–1.63)	75%	0.08	1.07 (0.99–1.16)	48%	0.04	0.88 (0.78–0.99)	65%
MM	319/370	0.49	0.87 (0.59–1.29)	0%	0.80 1	06 (0.70–1.58)	10%	0.36	1.18 (0.83–1.67)	30%	0.81	0.97 (0.76–1.25)	0%

Abbreviations: AL, acute leukemia; CL, chronic leukemia; NHL, non-Hodgkin’s lymphoma; HL, Hodgkin’s lymphoma; MM, multiple myeloma; OR, odds ratio; CI, confidence interval; NA, not available.

The values in bold represent there are statistically significant differences between cases and controls.

Data availability statement

Data sharing is not applicable to this article as no new data were created or analyzed in this study.